

- FOR IMMEDIATE RELEASE -

CLARITAS RX ANNOUNCES EXPANSION OF ADVISORY BOARD

South San Francisco, CA – 02/05/19 – Claritas Rx LLC, a data integration and analytics company focused on specialty biopharmaceutical products, announced today the expansion of its Advisory Board with two key appointments: Vita Cassese and Steven Fitzpatrick.

“Claritas Rx continues to position itself for sustainable growth and scale consistent with our strategic plan,” commented Michael Fitzgibbons, CEO of Claritas Rx. “Vita’s operational experience in biopharma companies, combined with her expertise in strategy for technology companies, will provide us with a valuable perspective. Steve’s deep expertise in the specialty pharmacy industry will be an asset to our board given our focus on the patient experience in specialty and orphan therapeutic areas.”

- Vita Cassese is the CEO of Mardon Management Advisors, a technology and analytics advisory firm that helps businesses capitalize on innovation and data to realize operational excellence and drive revenue growth. With over 30 years of experience as an operating executive and strategist, Vita is a senior advisor to Vestar Capital Partners and a member of the Technology and Healthcare Advisory Boards of Riverside Partners, responsible for identifying and qualifying potential technology and healthcare trends, investments and partnerships. As chief information officer of Pfizer’s Worldwide Pharmaceuticals Group, Vita led an organization of nearly 2,000 employees in 44 countries. While at Pfizer, Vita was instrumental in the creation and leadership of Pfizer’s Global Innovation organization.
- Steven Fitzpatrick retired as President of Accredo Health, Incorporated and Accredo Health Group, Inc. in 2011. Mr. Fitzpatrick joined Accredo in 2001 as President of its subsidiary, Sunrise Health Management, Inc., and was named President of Accredo Therapeutics, Inc., in February 2002. With the acquisition of Accredo by Medco Health Solutions, Inc., in August 2005, Mr. Fitzpatrick assumed responsibility for both Accredo Therapeutics and Accredo Specialty Care Services (formerly Medco Specialty Solutions). In March 2006, he became Chief Operating Officer of Accredo Health Group and was named President in 2008. He is also an independent Director of Fred's, Inc. Prior to joining Accredo, Mr. Fitzpatrick held senior management positions with Abbott Laboratories, Block Medical (infusion devices), PharmaThera (home infusion), Nations Healthcare (home infusion), Global Vision (PRK/Lasik surgery centers) and Veterinary Practice Management (veterinary practice roll - up).

The Claritas Rx Advisory Board currently includes:

- Kurt Hilzinger, CPA, is a Partner with Court Square Capital Partners, a private equity firm based in New York City, where he is focused on making investments in the healthcare industry. Since 2003, he has also been on the board of Humana, including serving as lead director from 2010 to 2014 when he became chairman of the Board. Previously, Kurt served as President and Chief Operating Officer and earlier as Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation, one of the world’s largest pharmaceutical services companies serving the United States, Canada and related global markets. In addition, Kurt also currently serves on the Board of NDC, Inc. (a Court Square portfolio company), the Board of Directors of Oncobiologics, Inc., and the Visiting Committee at the Ross School of Business at the University of Michigan.
- Dr. Kent Lieginger currently serves on the board of directors of Achaogen, Inc. and has most recently served as Senior Vice President, Managed Care and Customer Operations at Genentech, Inc., as well as Director of the Genentech Foundation since 2005. Prior to joining Genentech, he was Vice President, National Insurer and Employer Segment (Managed Markets Division) at GlaxoSmithKline plc, where he

also led teams in U.S. and global business development, finance, strategic contracting, manufacturing, marketing, and sales.

Claritas Rx plans to continue growing its group of advisors to expand the experience and perspective guiding the business.

ABOUT CLARITAS RX: Based in South San Francisco, CA, Claritas Rx is a digital health venture focused on biopharmaceutical distribution channels. Claritas leverages a proprietary cloud-based platform and deep manufacturer expertise to harvest valuable insights from specialty channels and other market data. The Claritas product platform and support services yield clear insights into commercial strategies and opportunities benefiting manufacturers, distribution partners and patients. For more information visit: www.claritasrx.com.

###